Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sun Pharma Advanced Research Company Ltd. Proxy Solicitation & Information Statement 2021

May 26, 2021

60740_rns_2021-05-26_17aff797-5694-4e89-8fca-eab707da22c1.pdf

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

SPARC/Sec/SE/2021-22/018

26[th] May 2021

National Stock Exchange of India Ltd, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

BSE Limited., Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001.

Dear Sir/ Madam,

  • Subject: Corrigendum to Notice of the Extra ordinary General Meeting of the Company on Tuesday, 8[th] June 2021 at 04.00 p.m.

Reference: Our letter dated 17[th] May 2021 under reference No. SPARC/Sec/SE/2021-22/016 with subject ‘Notice of the Extra-ordinary General Meeting of the Company.

With reference to the Notice convening Extra-Ordinary General Meeting of the Company on Tuesday, 8[th] June 2021 at 04.00 p.m. IST, through Video Conferencing (“VC”)/ Other Audio Visual Means (“OAVM”), (‘EGM Notice’ ) the Company has issued a ‘clarificatory’ Corrigendum to the shareholders, which is enclosed herewith for your record & dissemination.

Please note that the Corrigendum is being issued as a measure of abundant precaution with limited intent to clarify on disclosures relating to ultimate beneficial owners made in the table of para 6 of the explanatory statement of the EGM Notice.

This communication should be read along with the original EGM Notice dated 12[th] May 2021 which was submitted to the Exchange along with the above mentioned letter.

The EGM Notice along with the Corrigendum is also available on the website of the Company and can be accessed using the link: https://www.sparc.life/announcements-disclosures

Inconvenience caused in this regard is deeply regretted.

You are requested to kindly take the same on record.

Yours faithfully,

For Sun Pharma Advanced Research Company Ltd.,

==> picture [103 x 48] intentionally omitted <==

Debashis Dey

Company Secretary

Encls: A/a

==> picture [595 x 109] intentionally omitted <==

==> picture [81 x 36] intentionally omitted <==

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Registered Office : Plot No. 5 & 6/1, Savli G.I.D.C. Estate, Savli - Vadodara Highway, Manjusar, Vadodara - 391775, Gujarat, India. CIN: L73100GJ2006PLC047837 Website: www.sparc.life

CORRIGENDUM TO EGM NOTICE

The Notice of Extra-ordinary General Meeting dated May 12, 2021 (“ EGM Notice ”) shall be read with this corrigendum (“ Corrigendum ”).

This Corrigendum is issued as a measure of abundant precaution, with limited intent to clarify on disclosures relating to ultimate beneficial owners made in the table of para 6 of the Explanatory Statement of the EGM Notice.

  1. In the table under point 6 of the Explanatory Statement of the EGM Notice, the particulars of investors at Sr. Nos. 8, 20 and 34 shall be updated with the particulars of Ultimate Beneficial Owners and shall be read as follows:
Sr.
No.
Name of the
Proposed
Allottees
Ultimate Beneficial
Owners
(If applicable)
Pre Issue Equity
holding
Pre Issue Equity
holding
No. of
warrants
to be
allotted
Post issue Equity
holding (After
exercise of
Warrants) 1
Post issue Equity
holding (After
exercise of
Warrants) 1
No. of
shares
% No. of
shares
%
8 Abakkus
Growth Fund
– 1
1. Sunil Singhania5
2. Biharilal Deora5
NIL NA 14,04,494 14,04,494 0.43%
20 The Ram
Fund, L.P.
1. William I. Lee5
2. NancyC. Evertt5
NIL NA 4,74,269 4,74,269 0.14%
34 TIFF Global
Equity Fund,
L.P.
Richard J. Flannery5 NIL NA 62,808 62,808 0.02%
  1. The Notes under the table (under para 6 of the Explanatory Statement) shall be updated and read as follows:

  2. Note[3] shall be updated and read as follows:

3 Allottee is a FPI - Category 1 registered with SEBI.

  • After existing Note[4] , the following notes shall be added as Note[5] 5 Name of Senior managing Official(s)/Designated Partner(s )( since Allotee is a FPI – Category 2/ AIF registered with SEBI, with no single natural person’s stake being more than the threshold limit)

By order of the Board of Directors For Sun Pharma Advanced Research Company Limited

Debashis Dey Company Secretary

Place: Mumbai Date: May 25, 2021

Page 1 of 1